苏金单抗治疗自身免疫病研究进展

李芊 张进安

doi:10.3760/cma.j.issn.1673-4211.2018.05.004

国际生物制品学杂志 >

2018 , Vol. 41 >Issue 5: 225 - 229

DOI: https://doi.org/10.3760/cma.j.issn.1673-4211.2018.05.004

综述

苏金单抗治疗自身免疫病研究进展

李芊张进安

展开

201508 上海，复旦大学附属金山医院内分泌科（李芊）；201318 上海健康医学院附属周浦医院内分泌科-风湿科（张进安）

网络出版日期: 2025-08-16

收起

Advance in the treatment of autoimmune diseases with Secukinumab

Expand

*Department of Endocrinology, Jinshan Hospital of Fudan University, Shanghai 201508, China

Online published: 2025-08-16

Fold

摘要

白细胞介素（interleukin，IL）-17A是IL-17家族中功能最强的细胞因子。研究发现，IL-17A参与多种自身免疫炎性疾病的发生和发展，抑制IL-17A可能对这类疾病起治疗作用。随着对IL-17A研究的深入，人们已经开发出针对IL-17A的抗体。苏金单抗作为一种针对IL-17A的生物制剂，在自身免疫病治疗中具有广阔的应用前景。

关键词： 抗体,单克隆;白细胞介素17;自身免疫疾病

本文引用格式

李芊张进安 . 苏金单抗治疗自身免疫病研究进展[J]. 国际生物制品学杂志, 2018 , 41(5) : 225 -229 . DOI: 10.3760/cma.j.issn.1673-4211.2018.05.004

Abstract

Interleukin (IL)-17A is the most potent cytokine member of IL-17 family. Studies have showed that IL-17A is involved in the occurrence and development of a variety of autoimmune inflammatory diseases, and inhibitors of IL-17A may play an important role in the treatment of these diseases. With the deepening study of IL-17A, antibodies against IL-17A have been developed. Secukinumab has a promising future in the treatment of autoimmune diseases as a biological agent targeting IL-17A.

Key words： Antibodies,monoclonal; Interleukin-17; Autoimmune diseases

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

Abstract